Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217501 | 0.68 | IRAK4 (0.30) | — | |
| SCHEMBL1908658 | 0.66 | — | — | |
| SCHEMBL22724002 | 0.66 | HTT (0.36) | — | |
| SCHEMBL21570194 | 0.64 | NR1H4 (0.41) | — | |
| SCHEMBL17133304 | 0.64 | KDM4E (0.44) | — | |
| SCHEMBL21691208 | 0.64 | CCNE1 (0.34) | — | |
| SCHEMBL12945953 | 0.63 | — | — | |
| SCHEMBL27676623 | 0.61 | PDE10A (0.55) | — | |
| SCHEMBL22851643 | 0.59 | — | — | |
| SCHEMBL19669618 | 0.57 | CA2 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-09-03 | — | — | US | disclosed |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| EP-3511328-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-9174978-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9174978-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | GABRA1 2911/4885GABRG2 2747/4885GABRB3 2430/4885 |
| US-20200276169-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | GABRA1 2911/4885GABRG2 2747/4885GABRB3 2430/4885 |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | MGAM, MGAM2, BPGM | GABRA1 2911/4885GABRG2 2747/4885GABRB3 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.